Circular Arc Hyperbaric Hard Chamber Improve Memory Sitting Single Room

Hyperbaric Hard Chamber Improve Memory Circular Arc Hyperbaric Chamber Sitting Single Room WEIZI

Overview

What is Micro Hyperbaric Oxygen Therapy?
Micro Hyperbaric Oxygen Therapy (MHBOT) is a sophisticated medical treatment that involves exposing patients to a pressurized environment filled with highly concentrated oxygen, achieving a purity level of 96%. This unique therapeutic setting leverages the principle of increased pressure to enhance the solubility and diffusion of oxygen into the bloodstream and bodily tissues.

During MHBOT sessions, patients breathe in this enriched oxygen, allowing it to penetrate deeper into the body's structures. This process is particularly beneficial for tissues that may be experiencing reduced blood flow or oxygen supply due to injury, illness, or other conditions. By delivering oxygen directly to these areas, MHBOT supports healing and recovery.

China has emerged as a leader in the field of MHBOT, with a vast network of 2,107 hospitals across the country (including Hong Kong, Macau, and Taiwan) offering this advanced therapy. These hospitals are equipped with a total of over 5,600 medical-grade hyperbaric oxygen chambers, demonstrating the widespread adoption and recognition of MHBOT's therapeutic benefits. This trend underscores China's dedication to providing its citizens with access to innovative and effective medical treatments.

2019 Nobel Prize in Physiology or Medicine Results Explained

Oxygen utilisation and regulation are essential for the survival of higher life, and three scientists, William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza, have been awarded the 2019 Nobel Prize in Physiology or Medicine for their discovery of a mechanism related to cellular sensing and adaptation to oxygen availability. They discovered that hypoxia-inducible factor 1 (HIF-1) is widely present in acute and chronic hypoxic cells and is an important transcription factor for cellular adaptation to hypoxia.HIF-1 levels are regulated by oxygen content. Under hyperoxia, HIF-1 is modified and then degraded; under hypoxia, HIF-1 is not degraded and causes the expression of hypoxia-related genes, such as erythropoietin, through transcriptional regulation. This article introduces the discovery and basic molecular mechanism of HIF-1, and discusses its value in clinical application.

The major discovery of William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza in the pathway of hypoxia-inducible factor has laid the foundation for the study of the mechanism of cellular adaptation to hypoxia and opened a whole new horizon for researchers, which will pave the way for research and treatment of a variety of diseases such as anaemia, tumours and ischemic-hypoxic diseases. mechanism of anaemia, tumour and ischemic-hypoxic diseases, paving the way for research and treatment. Subsequent studies have broadened the regulatory network of the HIF pathway, and through a large number of scientific experiments and clinical studies, a variety of therapeutic drugs have been developed, bringing a new turn to the prevention and treatment of diseases. With scientists' further understanding of the mechanism of hypoxia adaptation, the research results in this field will also be applied to the treatment of more diseases.